." >> one key person who sat on the steering committee for these meetings was doctor bob rappaport - the head of the fda division that regulates painkiller drugs. >> this is the voice of doctor rappaport at the fda hearing on the drug application for zohydro. >> throughout the hearing, rappaport repeatedly instructed the committee to focus narrowly on whether zohydro worked to relieve pain, rather than whether it would worsen the opioid epidemic. >> they did redirect us a few times when we were getting a little more concerned about individual safety. >> when the committee voted against approval, rappaport rebuked them for unfairly penalizing the drug company. >> it's hard not to learn from history. we're supposed to learn from history and try not to repeat our mistakes. >> there is not a legal basis by which fda can say we don't need another opioid because we've already had a lot of bad experience. >> doctor judith kramer voted against zohydro. but she says the fda's powers are limited. >> the fda is required by law to fairly and uniformly apply the law. the people that were saying s